COSTA MESA, Calif. June 1, 2016–(BUSINESS WIRE)– Cerebain Biotech (OTCQB: CBBT) today announced that Governor Scott McCallum, former governor of Wisconsin, has received an invitation and will be participating in a US-Poland Health Care Summit. The conference will begin on June 17, 2016 and be held in Warsaw, Poland.
Governor McCallum will be presenting his research on healthcare innovation to a conference organized by the Federation of Polish Hospitals and the US Embassy. His presentation will include Cerebain’s efforts to develop a novel approach to the treatment for patients suffering from Alzheimer’s disease and dementia. The conference is designed to address opportunities for US-Poland cooperation within healthcare.
Mr. Eric Clemons, President and CEO of Cerebain, plans to attend the event. He and Governor McCallum will be meeting with private and institutional testing centers to facilitate potential partnerships for testing endeavors.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.